The Pharma Data

DECEMBER 17, 2020

COVID-19 vaccine developers are faced with an ethical quandary — whether to let phase 3 trial participants become “unblinded” and to receive authorized vaccines as they become available, which could hinder the collection of meaningful trial data. Pfizer, which has received emergency approvals in the U.S.

Vaccine 52

Vaccine Trials Long-Term Care Facilities FDA 52

The Pharma Data

DECEMBER 10, 2020

Food and Drug Administration advisory panel recommended on Thursday that the agency authorize the emergency use of Pfizer’s coronavirus vaccine, clearing the way for a national campaign to inoculate enough Americans to stop the spread of COVID-19. The FDA is expected to authorize the vaccine’s use within days, the Post reported.

Vaccine 52

Vaccine FDA Long-Term Care Facilities Hospitals 52

The Pharma Data

DECEMBER 2, 2020

2, 2020 – Britain became the first Western country to allow emergency use of a coronavirus vaccine on Wednesday, after approving Pfizer’s candidate in the race to inoculate millions of people around the globe. But there are daunting obstacles to the vaccine’s delivery to the masses. WEDNESDAY, Dec.

Vaccine 40

Vaccine Long-Term Care Facilities Hospitals Nurses 40

The Pharma Data

DECEMBER 4, 2020

Britain First to Approve Emergency Use of Pfizer’s COVID vaccine. Britain became the first Western country to allow emergency use of a coronavirus vaccine on Wednesday, approving Pfizer’s candidate in the race to inoculate millions of people around the globe.

Long-Term Care Facilities 52

Long-Term Care Facilities Vaccine Nurses Hospitals 52

The Pharma Data

DECEMBER 3, 2020

” Britain First to Approve Emergency Use of Pfizer’s COVID vaccine. Britain became the first Western country to allow emergency use of a coronavirus vaccine on Wednesday, approving Pfizer’s candidate in the race to inoculate millions of people around the globe. Grossman School of Medicine, told the Times.

Hospitals 52

Hospitals Long-Term Care Facilities Vaccine Nurses 52

The Pharma Data

JANUARY 26, 2021

Lilly has received feedback from front-line nurses and doctors administering these infusions regarding the complexity and time requirements for preparation and administration. It remains under review by the FDA. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19. .

Hospitals 52

Hospitals Treatment Long-Term Care Facilities Trials 52

The Pharma Data

NOVEMBER 9, 2020

“This emergency authorization allows us to make bamlanivimab available as a COVID-19 treatment for recently diagnosed, high-risk patients – adding a valuable tool for doctors fighting the now-increasing burden of this global pandemic,” said David A. Ricks, Lilly’s chairman and CEO. patients who recovered from COVID-19. .

Treatment 52

Treatment FDA Hospitals Long-Term Care Facilities 52